- Home
- BNGO vs TOVX Comparison
BNGO vs TOVX Comparison
Compare BNGO & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNGO | TOVX |
|---|---|---|
| Founded | 2003 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 10.4M |
| IPO Year | 2018 | 2012 |
Fundamental Metrics
Financial Performance| Metric | BNGO | TOVX |
|---|---|---|
| Price | $1.28 | $0.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $7.00 | $1.00 |
| AVG Volume (30 Days) | 288.8K | ★ 28.6M |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.50 | 89.07 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,000,735.00 | N/A |
| Revenue This Year | $14.99 | N/A |
| Revenue Next Year | $34.73 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.26 | N/A |
| 52 Week Low | $1.06 | $0.16 |
| 52 Week High | $5.50 | $1.50 |
Technical Indicators
Market Signals| Indicator | BNGO | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 55.48 | 62.26 |
| Support Level | $1.09 | $0.18 |
| Resistance Level | $1.64 | $0.53 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 66.68 | 49.30 |
Price Performance
Historical ComparisonAbout BNGO Bionano Genomics Inc.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.